Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Synergy Pharmaceuticals Rose 14.1% in August

By Maxx Chatsko - Sep 11, 2018 at 9:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The small-cap biopharma reported second-quarter 2018 earnings and two important business updates.

What happened

Shares of Synergy Pharmaceuticals (NASDAQ: SGYP) rose more than 14% last month, according to data provided by S&P Global Market Intelligence. The sub-$500 million company reported second-quarter and first-half 2018 operating results that were carried by impressive product revenue growth for Trulance, which is approved to treat two different gastrointestinal diseases.

The biopharma also announced that Trulance had been added to the Express Scripts 2019 National Preferred Formulary List, which should help to increase prescriptions of the medication, and a licensing deal for the product in China, which provided $12 million up front and will provide future royalties on sales.

A hand pulling the last bar in a bar chart taller than the rest.

Image source: Getty Images.

So what

The business delivered encouraging product revenue growth in the first half of this year compared to the same period of 2017, with sales up an astounding 764% to $20.8 million. In that same span, research-and-development expenses dropped 85%, and selling, general, and administrative expenses fell 22%. Rising sales and falling expenses helped to narrow the company's first-half 2018 net loss to $65.8 million, compared to $138.5 million in the prior-year period.

The gap should shrink further in the near future thanks to the expanded insurer coverage of Trulance and potential sales in China. If Synergy Pharmaceuticals can continue to execute on the product's commercialization and keep expenses to a minimum, then it will go a long way to helping the business inch toward profitability.

Now what

Synergy Pharmaceuticals appears to be on the right path. However, after reporting a first-half 2018 operating loss of nearly $68 million, there's a long way to go before the company can have a shot at profitability. Seeing as the company had just $61 million at the end of June 2018, it's likely that another capital raise will be needed before the end of the year -- even after accounting for the up-front payment for the licensing deal in China.

That shouldn't be dismissed by investors, especially considering the company has more than doubled its share count in the last three years, which has sapped potential gains for long-term shareholders. Given the sliding stock price in September so far, it seems Mr. Market is already preparing.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
338%
 
S&P 500 Returns
119%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/17/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.